APPLICATION OF A Glucocorticoid Composition for the Treatment of Severe and Uncontrolled Asthma

摘要

1. Inhaled glucocorticoid composition for use in the treatment of a patient suffering from severe and uncontrolled asthma, where the composition is administered in the form of a spray aerosol generated by an inhalation device, where the device is adapted (a) to emit a spray aerosol during the patient's inhalation phase at a speed of no more than about 20 l / min; (b) to emit at least about 0.4 L of the gas phase, including atomized aerosol and possibly aerosol-free air, into the inhalation phase of the total volume; and (c) emitting in the inhalation phase not more than about 150 ml of aerosol-free air before emitting the atomized aerosol, where the therapy further includes oral administration of a glucocorticoid in a daily dose that is not more than about 40 ml of prednisolone, or an equipotent dose of another glucocorticoid. 2. The inhaled glucocorticoid composition according to claim 1, comprising a glucocorticoid selected from fluticasone propionate, budesonide, beclomethasone dipropionate, cyclesonide, flunesolid, mometasone furoate and triamcinolone acetonide. The composition of claim 1, wherein the orally administered glucocorticoid is selected from hydrocortisone, dexamethasone, prednisone, prednisolone, and methylprednisolone. The composition according to claim 1, where the daily dose of an orally administered glucocorticoid is reduced during therapy by at least 30% relative to the initial daily dose. The composition according to claim 4, wherein the daily dose of an orally administered glucocorticoid is reduced to zero during therapy. The composition of claim 1, wherein the therapy does not include oral administration of a glucocorticoid. The composition according to claim 1, where